Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

Palumbo, R.; Sottotetti, Federico; Bernardo, Antônio

doi:10.1177/1758834016639873

Cited by 29 publications

(21 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is in agreement with the published data showing a greater risk of mild–moderate side effects associated with nab-paclitaxel treatment. In our study, we also found a significant impact of nab-paclitaxel on pain reduction and this was linked to better survival and improvement of QoL 29. We realize, however, that despite our results being in line with those reported in the literature, there are limits that must be taken into consideration, related for example, to the evaluation of the response and to the small size of the sample.…”

Section: Discussionsupporting

confidence: 83%

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

Luca¹,

Profita²,

Cicero³

2019

OTT

View full text Add to dashboard Cite

Objective Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim of this study was to evaluate nab-paclitaxel in Italian patients with MBC. Methods We conducted a retrospective analysis of 90 patients with histologically confirmed diagnosis of MBC. To evaluate the efficacy of nab-paclitaxel, overall survival (OS), progression-free survival (PFS), and overall response rate were the primary endpoints, whereas carbohydrate antigen 15.3 (Ca15.3) reduction, QoL, and tolerability were secondary endpoints. Results The median OS was 10.4 months, the median PFS was 6.8 months. A considerable difference Ca15.3 before and after treatment was observed. Descriptive and regression analyses were done to examine the associations between Ca15.3 response and OS, demonstrating good correlation, revealing that Ca15.3 reduction is an important predictor of OS. Conclusion Nab-paclitaxel is an effective and well-tolerated treatment of patients affected by MBC. The drug showed an improved tolerability profile. With all the limitations of the observational nature of our results, nab-paclitaxel has proven to be an effective and safe therapeutic option in patients with MBC.

show abstract

Section: Discussionsupporting

confidence: 83%

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

Luca¹,

Profita²,

Cicero³

2019

OTT

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6][7] Furthermore, other widely used drugs in this setting are vinorelbine, gemcitabine, ixabepilone (not approved by European Medicines Agency), nab-paclitaxel (where available) and liposomal anthracyclines. [8][9][10][11][12] Eribulin mesylate is an irreversible, non-taxane, microtubule growth inhibitor with a novel mechanism of action, also capable to overcome taxane resistance. 13 14 On the basis of the results of phase III trials, study 305 (EMBRACE) in which median overall survival (OS) was significantly longer with eribulin compared with the treatment of physician's choice (13.1 vs 10.6 months, p=0.041) and study 301, and the pooled analysis of both aforementioned trials, 7 15 16 eribulin was approved in the USA (November 2010) and in Europe (March 2011) for the treatment of MBC previously treated with at least two lines of chemotherapy, including anthracyclines and taxanes, and with at least one chemotherapy regimen, respectively.…”

Section: Key Questionsmentioning

confidence: 99%

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

et al. 2017

View full text Add to dashboard Cite

BackgroundOn the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, and at least one chemotherapeutic regimen for metastatic disease.MethodsIn our study, we investigated the efficacy and tolerability of eribulin as second or further line chemotherapy in 137 women affected by aBC.ResultsEribulin as monotherapy provided benefit in terms of progression-free survival (PFS), response rate (RR) and disease control rate (DCR) independently of its use as second or late-line therapy. The overall RR and DCR were 17.5% and 64%, respectively. In particular, DCR and overall RR were 50% and 13.6%, 65.4% and 21.1%, 70.4% and 14.8% and 66.7% and 16.7% in second, third, fourth and further lines of treatment, respectively. Median PFS (mPFS) according to the line of therapy was 5.7, 6.3, 4.5 and 4.0 months in patients treated with eribulin in second, third, fourth and over the fourth line, respectively. No significant difference in terms of mPFS was found between the various BC subtypes. Overall, eribulin resulted safe and most adverse events were of grade 1 or 2 and easily manageable. Grades 3–4 toxicities were neutropaenia and neurotoxicity.ConclusionsWith the limitations due to the observational nature of our findings, eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with aBC.

show abstract

“…Numerous therapeutic drugs are delivered by HSA [31]. For example, the albumin paclitaxel (PTX) nanoparticle (Abraxane ® ) has already been approved by the FDA for the treatment of metastatic breast cancer [32, 33]. However, a major drawback of the conventional method for Abraxane ® preparation is the need for toxic chlorinated organic solvents [34].…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation

Sun

et al. 2019

BioMed Eng OnLine

View full text Add to dashboard Cite

BackgroundDocetaxel (DTX) is an anticancer drug that is currently formulated with polysorbate 80 and ethanol (50:50, v/v) in clinical use. Unfortunately, this formulation causes hypersensitivity reactions, leading to severe side-effects, which have been primarily attributed to polysorbate 80.MethodsIn this study, a DTX-loaded human serum albumin (HSA) nanoparticle (DTX-NP) was designed to overcome the hypersensitivity reactions that are induced by polysorbate 80. The methods of preparing the DTX-NPs have been optimized based on factors including the drug-to-HSA weight ratio, the duration of HSA incubation, and the choice of using a stabilizer. Synthesized DTX-NPs were characterized with regard to their particle diameters, drug loading capacities, and drug release kinetics. The morphology of the DTX-NPs was observed via scanning electron microscopy (SEM) and the successful preparation of DTX-NPs was confirmed via differential scanning calorimetry (DSC). The cytotoxicity and cellular uptake of DTX-NPs were investigated in the non-small cell lung cancer cell line A549 and the maximum tolerated dose (MTD) of DTX-NPs was evaluated via investigations with BALB/c mice.ResultsThe study showed that the loading capacity and the encapsulation efficiency of DTX-NPs prepared under the optimal conditions was 11.2 wt% and 63.1 wt%, respectively and the mean diameter was less than 200 nm, resulting in higher permeability and controlled release. Similar cytotoxicity against A549 cells was exhibited by the DTX-NPs in comparison to DTX alone while higher maximum tolerated dose (MTD) with the DTX-NPs (75 mg/kg) than with DTX (30 mg/kg) was demonstrated in mice, suggesting that the DTX-NPs prepared with HSA yielded similar anti-tumor activity but were accompanied by less systemic toxicity than solvent formulated DTX.ConclusionsDTX-NPs warrant further investigation and are promising candidates for clinical applications.

show abstract

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

Cited by 29 publications

References 97 publications

<p>Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life</p>

<p>Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life</p>

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation

Contact Info

Product

Resources

About